Literature DB >> 21749497

Demyelination can proceed independently of axonal degradation during Wallerian degeneration in wlds mice.

Hitomi Takada1, Shigeki Yuasa, Toshiyuki Araki.   

Abstract

Peripheral nerve injury induces axonal degeneration and demyelination, which are collectively referred to as Wallerian degeneration. It is generally assumed that axonal degeneration is a trigger for the subsequent demyelination processes such as myelin destruction and de-differentiation of Schwann cells, but the detailed sequence of events that occurs during this initial phase of demyelination following axonal degeneration remains unclear. Here we performed a morphological analysis of injured sciatic nerves of wlds mice, a naturally occurring mutant mouse in which Wallerian degeneration shows a significant delay. The slow Wallerian degerenation phenotype of the wlds mutant mice would enable us to dissect the events that take place during the initial phase of demyelination. Ultrastrucural analysis using electron microscopy showed that the initial process of myelin destruction was activated in injured nerves of wlds mice even though they exhibit morphologically complete protection of axons against nerve injury. We also found that some intact axons were completely demyelinated in degenerating nerves of wlds mice. Furthermore, we observed that de-differentiation of myelinating Schwann cells gradually proceeded even though the axons remained morphologically intact. These data suggest that initiation and progression of demyelination in injured peripheral nerves is, at least in part, independent of axonal degeneration.
© 2011 The Authors. European Journal of Neuroscience © 2011 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21749497     DOI: 10.1111/j.1460-9568.2011.07783.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  1 in total

1.  Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.

Authors:  Shailender Singh; Tobias Dallenga; Anne Winkler; Shanu Roemer; Brigitte Maruschak; Heike Siebert; Wolfgang Brück; Christine Stadelmann
Journal:  J Neuroinflammation       Date:  2017-03-17       Impact factor: 8.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.